Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma

Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaikh, Atik Badshah, Li, Fangfei, Li, Min, He, Bing, He, Xiaojuan, Chen, Guofen, Guo, Baosheng, Li, Defang, Jiang, Feng, Dang, Lei, Zheng, Shaowei, Liang, Chao, Liu, Jin, Lu, Cheng, Liu, Biao, Lu, Jun, Wang, Luyao, Lu, Aiping, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848962/
https://www.ncbi.nlm.nih.gov/pubmed/27058531
http://dx.doi.org/10.3390/ijms17040506
_version_ 1782429457919770624
author Shaikh, Atik Badshah
Li, Fangfei
Li, Min
He, Bing
He, Xiaojuan
Chen, Guofen
Guo, Baosheng
Li, Defang
Jiang, Feng
Dang, Lei
Zheng, Shaowei
Liang, Chao
Liu, Jin
Lu, Cheng
Liu, Biao
Lu, Jun
Wang, Luyao
Lu, Aiping
Zhang, Ge
author_facet Shaikh, Atik Badshah
Li, Fangfei
Li, Min
He, Bing
He, Xiaojuan
Chen, Guofen
Guo, Baosheng
Li, Defang
Jiang, Feng
Dang, Lei
Zheng, Shaowei
Liang, Chao
Liu, Jin
Lu, Cheng
Liu, Biao
Lu, Jun
Wang, Luyao
Lu, Aiping
Zhang, Ge
author_sort Shaikh, Atik Badshah
collection PubMed
description Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. This review summarizes the current development of molecular mechanisms and targets for osteosarcoma. Therapies that target these mechanisms with updated information on clinical trials are also reviewed. Meanwhile, we further discuss novel therapeutic targets and OS-targeting drug delivery systems. In conclusion, a full insight in OS pathogenesis and OS-targeting strategies would help us explore novel targeted therapies for metastatic osteosarcoma.
format Online
Article
Text
id pubmed-4848962
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48489622016-05-04 Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma Shaikh, Atik Badshah Li, Fangfei Li, Min He, Bing He, Xiaojuan Chen, Guofen Guo, Baosheng Li, Defang Jiang, Feng Dang, Lei Zheng, Shaowei Liang, Chao Liu, Jin Lu, Cheng Liu, Biao Lu, Jun Wang, Luyao Lu, Aiping Zhang, Ge Int J Mol Sci Review Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. This review summarizes the current development of molecular mechanisms and targets for osteosarcoma. Therapies that target these mechanisms with updated information on clinical trials are also reviewed. Meanwhile, we further discuss novel therapeutic targets and OS-targeting drug delivery systems. In conclusion, a full insight in OS pathogenesis and OS-targeting strategies would help us explore novel targeted therapies for metastatic osteosarcoma. MDPI 2016-04-06 /pmc/articles/PMC4848962/ /pubmed/27058531 http://dx.doi.org/10.3390/ijms17040506 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shaikh, Atik Badshah
Li, Fangfei
Li, Min
He, Bing
He, Xiaojuan
Chen, Guofen
Guo, Baosheng
Li, Defang
Jiang, Feng
Dang, Lei
Zheng, Shaowei
Liang, Chao
Liu, Jin
Lu, Cheng
Liu, Biao
Lu, Jun
Wang, Luyao
Lu, Aiping
Zhang, Ge
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
title Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
title_full Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
title_fullStr Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
title_full_unstemmed Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
title_short Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
title_sort present advances and future perspectives of molecular targeted therapy for osteosarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848962/
https://www.ncbi.nlm.nih.gov/pubmed/27058531
http://dx.doi.org/10.3390/ijms17040506
work_keys_str_mv AT shaikhatikbadshah presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT lifangfei presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT limin presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT hebing presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT hexiaojuan presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT chenguofen presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT guobaosheng presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT lidefang presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT jiangfeng presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT danglei presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT zhengshaowei presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT liangchao presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT liujin presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT lucheng presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT liubiao presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT lujun presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT wangluyao presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT luaiping presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma
AT zhangge presentadvancesandfutureperspectivesofmoleculartargetedtherapyforosteosarcoma

Ejemplares similares